S Köpke1, J Kasper2, P Flachenecker3, H Meißner3, A Brandt4, B Hauptmann4,5, G Bender6, I Backhus7,8, A C Rahn7,8, J Pöttgen8, E Vettorazzi9, C Heesen8. 1. 1 Institute of Social Medicine, University of Lübeck, Lübeck, Germany. 2. 2 Department of Health and Caring Sciences, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway. 3. 3 Neurological Rehabilitation Center Quellenhof, Bad Wildbad, Germany. 4. 4 Department of Neurology, Segeberger Kliniken, Bad Segeberg, Germany. 5. 5 Department of Therapeutic Sciences, MSH Medical School Hamburg, Hamburg, Germany. 6. 6 RehaCentre Hamburg, Hamburg, Germany. 7. 7 Unit of Health Sciences and Education, MIN Faculty, University of Hamburg, Hamburg, Germany. 8. 8 Institute of Neuroimmunology & Multiple Sclerosis and Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 9. 9 Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Abstract
OBJECTIVE: To investigate the effectiveness of a multi-component evidence-based education programme on disease modifying therapies in multiple sclerosis. DESIGN: Controlled trial with two consecutive patient cohorts and a gap of two months between cohorts. SETTING: Three neurological rehabilitation centres. SUBJECTS:Patients with multiple sclerosis within rehabilitation. INTERVENTIONS: Control group (CG) participants were recruited and received standard information. Two months later, intervention group (IG) participants were recruited and received a six-hour nurse-led interactive group education programme consisting of two parts and a comprehensive information brochure. MAIN MEASURES: Primary endpoint was "informed choice", comprising of adequate risk knowledge in combination with congruency between attitude towards immunotherapy and actual immunotherapy uptake. Further outcomes comprised risk knowledge, decision autonomy, anxiety and depression, self-efficacy, and fatigue. RESULTS:A total of 156 patients were included (IG=75, CG=81). The intervention led to significantly more participants with informed choice (IG: 47% vs. CG: 23%, P=0.004). The rate of persons with adequate risk knowledge was significantly higher in the IG two weeks after the intervention (IG: 54% vs. CG: 31%, P=0.007), but not after six months (IG: 48% vs. CG: 31%, P=0.058). No significant differences were shown for positive attitude towards disease modifying therapy (IG: 62% vs. CG: 71%, P=0.29) and for disease modifying therapy status after six months (IG: 61.5% vs CG: 68.6%, P=0.39). Also no differences were found for autonomy preferences and decisional conflict after six months. CONCLUSION: Delivering evidence-based information on multiple sclerosis disease modifying therapies within a rehabilitation setting led to a marked increase of informed choices.
RCT Entities:
OBJECTIVE: To investigate the effectiveness of a multi-component evidence-based education programme on disease modifying therapies in multiple sclerosis. DESIGN: Controlled trial with two consecutive patient cohorts and a gap of two months between cohorts. SETTING: Three neurological rehabilitation centres. SUBJECTS:Patients with multiple sclerosis within rehabilitation. INTERVENTIONS: Control group (CG) participants were recruited and received standard information. Two months later, intervention group (IG) participants were recruited and received a six-hour nurse-led interactive group education programme consisting of two parts and a comprehensive information brochure. MAIN MEASURES: Primary endpoint was "informed choice", comprising of adequate risk knowledge in combination with congruency between attitude towards immunotherapy and actual immunotherapy uptake. Further outcomes comprised risk knowledge, decision autonomy, anxiety and depression, self-efficacy, and fatigue. RESULTS: A total of 156 patients were included (IG=75, CG=81). The intervention led to significantly more participants with informed choice (IG: 47% vs. CG: 23%, P=0.004). The rate of persons with adequate risk knowledge was significantly higher in the IG two weeks after the intervention (IG: 54% vs. CG: 31%, P=0.007), but not after six months (IG: 48% vs. CG: 31%, P=0.058). No significant differences were shown for positive attitude towards disease modifying therapy (IG: 62% vs. CG: 71%, P=0.29) and for disease modifying therapy status after six months (IG: 61.5% vs CG: 68.6%, P=0.39). Also no differences were found for autonomy preferences and decisional conflict after six months. CONCLUSION: Delivering evidence-based information on multiple sclerosis disease modifying therapies within a rehabilitation setting led to a marked increase of informed choices.
Authors: Anne Christin Rahn; Alessandra Solari; Heleen Beckerman; Richard Nicholas; David Wilkie; Christoph Heesen; Andrea Giordano Journal: Int J MS Care Date: 2020-12-28
Authors: Andrea Giordano; Katrin Liethmann; Sascha Köpke; Jana Poettgen; Anne Christin Rahn; Jelena Drulovic; Yesim Beckmann; Jaume Sastre-Garriga; Ian Galea; Marco Heerings; Peter Joseph Jongen; Eik Vettorazzi; Alessandra Solari; Christoph Heesen Journal: PLoS One Date: 2018-11-29 Impact factor: 3.240
Authors: Anna Barabasch; Karin Riemann-Lorenz; Christopher Kofahl; Jutta Scheiderbauer; Desiree Eklund; Ingo Kleiter; Jürgen Kasper; Sascha Köpke; Susanne Lezius; Antonia Zapf; Anne Christin Rahn; Christoph Heesen Journal: Pilot Feasibility Stud Date: 2021-01-07